Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline PLC

www.gsk.com

Latest From GlaxoSmithKline PLC

NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications

GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from he first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.

OTC Drugs Regulation

Generics Players Dominating New OTC Launches In Germany

An analysis by Sempora Consulting of the German OTC market in 2018 shows that generic products dominate new OTC product launches.
Health OTC Drugs

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.
Business Strategies Sales & Earnings

AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval

AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.

Approvals Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register